2 research outputs found
De-Novo Designed Library of Benzoylureas as Inhibitors of BCL‑X<sub>L</sub>: Synthesis, Structural and Biochemical Characterization
The
prosurvival BCL-2 proteins are attractive yet challenging targets
for medicinal chemists. Their involvement in the initiation and progression
of many, if not all, tumors makes them prime targets for developing
new anticancer therapies. We present our approach based on de novo
structure-based drug design. Using known structural information from
complexes engaging opposing members of the BCL-2 family of proteins,
we designed peptidomimetic compounds using a benzoylurea scaffold
to reproduce key interactions between these proteins. A library stemming
from the initial de novo designed scaffold led to the discovery of
ligands with low micromolar potency (<i>K</i><sub>D</sub> = 4 ÎĽM) and selectivity for BCL-X<sub>L</sub>. These compounds
bind in the canonical BH3 binding groove in a binding mode distinct
from previously known BCL-2 inhibitors. The results of our study provide
insight into the design of a new class of antagonists targeting a
challenging class of protein–protein interactions
Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl‑X<sub>L</sub>
Developing potent
molecules that inhibit Bcl-2 family mediated
apoptosis affords opportunities to treat cancers via reactivation
of the cell death machinery. We describe the hit-to-lead development
of selective Bcl-X<sub>L</sub> inhibitors originating from a high-throughput
screening campaign. Small structural changes to the hit compound increased
binding affinity more than 300-fold (to IC<sub>50</sub> < 20 nM).
This molecular series exhibits drug-like characteristics, low molecular
weights (<i>M</i><sub>w</sub> < 450), and unprecedented
selectivity for Bcl-X<sub>L</sub>. Surface plasmon resonance experiments
afford strong evidence of binding affinity within the hydrophobic
groove of Bcl-X<sub>L</sub>. Biological experiments using engineered
Mcl-1 deficient mouse embryonic fibroblasts (MEFs, reliant only on
Bcl-X<sub>L</sub> for survival) and Bax/Bak deficient MEFs (insensitive
to selective activation of Bcl-2-driven apoptosis) support a mechanism-based
induction of apoptosis. This manuscript describes the first series
of selective small-molecule inhibitors of Bcl-X<sub>L</sub> and provides
promising leads for the development of efficacious therapeutics against
solid tumors and chemoresistant cancer cell lines